Long Island Capital Alliance Announces Participants forBiotech Technology Transfer Capital Forum
Event to be Held on June 14 in Collaboration with Cold Spring Harbor LaboratoryMelville, NY – June 7, 2013 – The Long Island Capital Alliance (“LICA”), the leading non-profit capital formation and business development organization serving regional companies, today announced the presenting companies and panelists for its Biotech Technology Transfer Capital Forum to be held on June 14, 2013. The capital forum is being held in collaboration with Cold Spring Harbor Laboratory (“CSHL”) in an effort to facilitate the formation and acceleration of high-growth businesses on Long Island, based on technologies developed at CSHL.
CSHL scientists will present some of the exciting new technologies developed there to biotech investors, and investors will have an opportunity to meet and establish relationships with the CSHL officials and scientists. Each of the underlying technologies LICA selected for presentation at the event is believed to represent catalysts for significant growth which will be attractive to investors and other financial backers. CSHL is continuing to expand its outreach and partnerships toward building locally-based companies around its technologies using the “technology transfer” concept.
Technology transfer involves the use of inventions, processes, and knowledge developed by subject matter experts to create and enhance private sector businesses. Technology transfer involves a wide range of approaches to get technologies to market, including licensing to larger, more established companies, establishing equity transactions to provide technology to startup businesses, and entering into research and development agreements, including Small Business Innovation Research (SBIR) programs, to collaboratively advance the technology toward commercialization.
A panel of investors and technology transfer experts will describe the process of financing and building companies around technological discoveries.
Biotech Technology Transfer Capital Forum on June 14, 2013 – ParticipantsPanel of InvestorsGreg Blake: Mr. Blake founded Brocair Partners in 2004 with a focus on providing advisory services to healthcare companies on a variety of merger and acquisition, financing, and strategic matters. Mr. Blake has an exceptional set of senior-level relationships in the healthcare industry, and has worked with clients that range from large publicly-traded healthcare companies to small family-owned businesses.
Larry Chaityn: Larry Chaityn is a Managing Director and Head of Global Health care Banking at Kaminski Partners, a global investment bank. He is responsible for overseeing the day-to-day operations of the bank including deal sourcing, deal review, due diligence investigation and client-facing operations. He has 14 years of health care/life sciences advisory experience, is an active member in the venture capital and angel investment communities and in the National Association of Health Services Executives.
Scott Livingston: Mr. Livingston is the President of Livingston Securities, an investment banking firm that specializes in the nanotechnology and biosciences industries. Mr. Livingston has hosted the annual "Livingston Nanotechnology Conference," Wall Street's largest annual nanotechnology investor conference, since 2005.
Steve Winick: Steve Winick is a principal of Topspin Partners, one of Long Island's leading venture capital firms. Steve previously served as CIO of Honeywell International's $2B security group. He had been with Honeywell (and the Ademco division of Pittway Corp., before its acquisition by Honeywell in 2000) for over 21 years as CTO of the security business, as well as
founder and president of its wireless communications services business.
Presenting Companies and TechnologiesA Novel Treatment for Diabetes, Obesity and Cancer: exploiting an oral dosage of a key regulator of insulin, leptin and HER2 oncogene function. (Professor Nicholas Tonks, FRS)
RapidCaP: the next generation platform to cure metastatic prostate cancer. (Professor Lloyd Trotman)
Velocin-N(TM): a new enzyme that enables faster, more sensitive and more selective detection of proteins (the miniature machines and structures of life) in mass spectrometers. (Dr. John Wilson)
Wilson Advanced Research: develops products with novel health, social and commercial benefit, spanning a wide range from consumer products to environmental clean-up, including a simple solution to eliminate the largest reservoir of bacteria--including MURSA and E. coli 0157-- from homes. (Dr. John Wilson)
LICA, in collaboration with CSHL, will host the Biotech Technology Transfer Capital Forum on June 14, 2013 from 8:00 a.m. to 10:30 a.m. at 68 South Service Road, Melville, NY. The capital forum provides an opportunity to meet CSHL scientists, industry executives, capital providers, entrepreneurs, and businesses seeking capital, as well as to hear a panel of industry experts discuss financing alternatives for biotech technology transfer-based businesses.
For more information about the event, please contact LICA today or register online.
Originally published on licapital.org.